Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity
- Conditions
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT01473732
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Emory University
- Target Recruit Count
- 43
- Registration Number
- NCT01470209
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Emory University
- Target Recruit Count
- 13
- Registration Number
- NCT01469572
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2015-04-03
- Target Recruit Count
- 30
- Registration Number
- NCT01469884
- Locations
- 🇧🇷
Irmandade Da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Everolimus in Refractory Testicular Germ Cell Cancer
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- National Cancer Institute, Slovakia
- Target Recruit Count
- 15
- Registration Number
- NCT01466231
- Locations
- 🇸🇰
National Cancer Institute, Bratislava, Slovakia
Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
- Conditions
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Hans J. van der Vliet, MD, PhD
- Target Recruit Count
- 96
- Registration Number
- NCT01462214
- Locations
- 🇳🇱
Isala Klinieken Zwolle, Zwolle, Netherlands
🇳🇱Medisch Centrum Alkmaar, Alkmaar, Netherlands
🇳🇱NKI-AVL, Amsterdam, Netherlands
Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults
- Conditions
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Deise de Boni Monteiro de Carvalho
- Target Recruit Count
- 30
- Registration Number
- NCT01455649
- Locations
- 🇧🇷
Hospital federal de Bonsucesso, Rio de Janeiro, Brazil
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 73
- Registration Number
- NCT01453504
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2011-11-18
- Target Recruit Count
- 30
- Registration Number
- NCT01446484
- Locations
- 🇷🇺
The Russian State Medical University, Moscow, Russian Federation
🇷🇺Boris Petrovsky Scientific Center of Surgery Russian Academy of Medical Sciencies, Moscow, Russian Federation
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01442090
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.